-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Immuneering, Raises Price Target to $18

Benzinga·07/20/2026 10:33:53
Listen to the news
Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.